Francesca Gabriele1, Maria Trachana2, Maria Simitsopoulou1, Polixeni Pratsidou-Gertsi2, Elias Iosifidis1, Zoi Dorothea Pana1, Emmanuel Roilides3. 1. Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-546 42, Thessaloniki, Greece. 2. Pediatric Immunology and Rheumatology Referral Center, 1st Department of Pediatrics, Thessaloniki, Greece. 3. Infectious Diseases Unit, 3rd Department of Pediatrics, Aristotle University, Hippokration Hospital, Konstantinoupoleos 49, GR-546 42, Thessaloniki, Greece. roilides@med.auth.gr.
Abstract
BACKGROUND: To evaluate the performance of the Quantiferon®-TB Gold In-Tube (QFT-IT) interferon (IFN)-γ assay for the detection of latent tuberculosis infection (LTBI) in children receiving anti-rheumatic treatment in a tertiary referral hospital of Northern Greece. METHODS: A total of 79 consecutive children receiving anti-rheumatic treatment [of which 18 screened prior to antitumor necrosis factor (TNF)-α treatment] were tested using Mantoux tuberculin skin test (TST) and QFT-IT. Association of both tests with risk factors for latent tuberculosis and Bacillus Calmette-Guerin immunization was determined. Influence of age, TNF-α inhibitors, systemic corticosteroids, conventional disease modifying anti-rheumatic drugs (DMARDs) and total duration of therapy on the QFT-IT mitogen-induced response was evaluated. RESULTS: Agreement between TST and QFT-IT results was moderate (k=0.38). Frequency of QFT-IT indeterminate results was low (2.5%). In patients with risk factors for LTBI, the odds of a positive IFN-γ assay was increased by a factor of 27.6 (P=0.002), whereas there was no positive TST. There was a significant difference in the mitogen-induced IFN-γ secretion among various treatments (P=0.038). TNF-α inhibitors were associated with increased mitogen-induced IFN-γ secretion compared to monotherapy with conventional DMARDs (P=0.008). All children screened prior to anti-TNF-α treatment exhibited a negative QFT-IT and no active TB disease was detected during a 2-year follow-up. CONCLUSIONS: QFT-IT may be a more reliable test than TST for detection of LTBI in children with rheumatic diseases receiving anti-rheumatic treatment. Drug regimen might influence the mitogen-induced IFN-γ secretion and the effect of TNF-α inhibitors might vary according to the specific agent administered.
BACKGROUND: To evaluate the performance of the Quantiferon®-TB Gold In-Tube (QFT-IT) interferon (IFN)-γ assay for the detection of latent tuberculosis infection (LTBI) in children receiving anti-rheumatic treatment in a tertiary referral hospital of Northern Greece. METHODS: A total of 79 consecutive children receiving anti-rheumatic treatment [of which 18 screened prior to antitumor necrosis factor (TNF)-α treatment] were tested using Mantoux tuberculin skin test (TST) and QFT-IT. Association of both tests with risk factors for latent tuberculosis and Bacillus Calmette-Guerin immunization was determined. Influence of age, TNF-α inhibitors, systemic corticosteroids, conventional disease modifying anti-rheumatic drugs (DMARDs) and total duration of therapy on the QFT-IT mitogen-induced response was evaluated. RESULTS: Agreement between TST and QFT-IT results was moderate (k=0.38). Frequency of QFT-IT indeterminate results was low (2.5%). In patients with risk factors for LTBI, the odds of a positive IFN-γ assay was increased by a factor of 27.6 (P=0.002), whereas there was no positive TST. There was a significant difference in the mitogen-induced IFN-γ secretion among various treatments (P=0.038). TNF-α inhibitors were associated with increased mitogen-induced IFN-γ secretion compared to monotherapy with conventional DMARDs (P=0.008). All children screened prior to anti-TNF-α treatment exhibited a negative QFT-IT and no active TB disease was detected during a 2-year follow-up. CONCLUSIONS: QFT-IT may be a more reliable test than TST for detection of LTBI in children with rheumatic diseases receiving anti-rheumatic treatment. Drug regimen might influence the mitogen-induced IFN-γ secretion and the effect of TNF-α inhibitors might vary according to the specific agent administered.
Authors: William S Mow; Maria T Abreu-Martin; Konstantinos A Papadakis; Howard E Pitchon; Stephan R Targan; Eric A Vasiliauskas Journal: Clin Gastroenterol Hepatol Date: 2004-04 Impact factor: 11.382
Authors: R Diel; D Goletti; G Ferrara; G Bothamley; D Cirillo; B Kampmann; C Lange; M Losi; R Markova; G B Migliori; A Nienhaus; M Ruhwald; D Wagner; J P Zellweger; E Huitric; A Sandgren; D Manissero Journal: Eur Respir J Date: 2010-10-28 Impact factor: 16.671
Authors: A M Mandalakas; A C Hesseling; N N Chegou; H L Kirchner; X Zhu; B J Marais; G F Black; N Beyers; G Walzl Journal: Int J Tuberc Lung Dis Date: 2008-04 Impact factor: 2.373
Authors: Noëmi R Meier; Thomas Volken; Marc Geiger; Ulrich Heininger; Marc Tebruegge; Nicole Ritz Journal: Front Pediatr Date: 2019-05-29 Impact factor: 3.418
Authors: Sara Parigi; Amelia Licari; Sara Manti; Gian Luigi Marseglia; Maria Angela Tosca; Michele Miraglia Del Giudice; Carlo Caffarelli; Mauro Calvani; Alberto Martelli; Fabio Cardinale; Claudio Cravidi; Marzia Duse; Elena Chiappini Journal: Acta Biomed Date: 2020-09-15